Abstract
Purpose
The aim of this study is to investigate the impact of chemotherapy and/or radiotherapy on disease-free survival and overall survival for patients with stage II thymic carcinoma.
Methods
We retrospectively evaluated the outcome of 31 patients with Masaoka stage II thymic carcinoma who were treated between 1995 and 2009 in Zhejiang Cancer Hospital. Survival curves were plotted using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis.
Results
Thirty-one patients were included in current study. The most common histological subtypes were squamous cell carcinoma (48.4 %), followed by undifferentiated carcinoma (19.4 %) and neuroendocrine tumor (19.4 %).The 5-year disease-free survival and overall survival rate was 74.6 and 89.5 %, respectively. Univariate and multivariate analysis revealed that radiotherapy and/or chemotherapy did not statistically associated with disease-free survival and overall survival.
Conclusion
Our result indicated that adjuvant therapy after complete resection could not impact the disease-free survival and overall survival of patients with stage II thymic carcinoma.
This is a preview of subscription content, log in via an institution to check access.
References
Kim DJ, Yang WI, Choi SS, Kim KD, Chung KY (2005) Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors: a clinicopathologic study of 108 patients and literature review. Chest 127:755–761
Kitami A, Suzuki T, Kamio Y et al (2001) Chemotherapy of thymic carcinoma: analysis of seven cases and review of the literature. Jpn J Clin Oncol 31:601–604
Kondo K, Monden Y (2003a) Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 76:878–884
Kondo K, Monden Y (2003b) Lymphogenous and hematogenous metastasis of thymic epithelial tumors. Ann Thorac Surg 76:1859–1864
Latz D, Schraube P, Oppitz U et al (1997) Invasive thymoma: treatment with postoperative radiation therapy. Radiology 204:859–864
Lee CY, Bae MK, Park IK, Kim DJ, Lee JG, Chung KY (2009) Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a single institution. Eur J Cardiothorac Surg 36:159–163
Nonaka T, Tamaki Y, Higuchi K et al (2004) The role of radiotherapy for thymic carcinoma. Jpn J Clin Oncol 34:722–726
Sakai M, Onuki T, Inagaki M, Yamaoka M, Kitazawa S, Kobayashi K, Iguchi K, Kikuchi S, Goto Y, Onizuka M, Sato Y (2013) Early-stage thymic carcinoma: is adjuvant therapy required? J Thorac Dis 5:161–164
Wick MR, Weiland LH, Scheithauer BW, Bernatz PE (1982) Primary thymic carcinomas. Am J Surg Pathol 6:451–470
Yano M, Sasaki H, Yokoyama T, Yukiue H, Kawano O, Suzuki S, Fujii Y (2008a) Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol 3:265–269
Yano M, Sasaki H, Yokoyama T et al (2008b) Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol 3:265–269
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Song, Z., Zhang, Y. Adjuvant therapy in stage II thymic carcinoma. J Cancer Res Clin Oncol 140, 349–352 (2014). https://doi.org/10.1007/s00432-013-1562-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-013-1562-6